"[There is] an opportunity within the healthcare space to create tools within the electronic medical record system that more effectively link symptoms and their duration, diagnostic study results, and ...

Twenty NMOSD patients representing the general patient population were convened to discuss their employment experiences. Participants reported employment issues due to high disease burdens, a lack of ...

Most cases of NMOSD present with symptoms of either optic neuritis or transverse myelitis, if not symptoms of both, but some cases of brain abnormalities without optic neuritis or longitudinally ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

Please provide your email address to receive an email when new articles are posted on . Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated ...

SAN DIEGO — Treatment with daratumumab, a monoclonal antibody approved to treat multiple myeloma, was associated with a significant decrease in relapse risk in patients with aquaporin-4 immunoglobulin ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Neuromyelitis optica spectrum disorder (NMOSD) and related demyelinating diseases, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), represent a spectrum of autoimmune ...

Neuromyelitis optica spectrum disorder (NMOSD) is a condition that affects your eyes and spinal cord. It is an autoimmune disorder where the immune system attacks healthy cells in the nervous system, ...

There are predominantly 2 patterns of NMOSD: monophasic and relapsing. Monophasic NMOSD is diagnosed in approximately 10% of patients and occurs when 1 or both optic nerves and spinal cord are ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...